Regulation and Function of the Interleukin 13 Receptor Alpha 2 During a T Helper Cell Type 2-dominant Immune Response
Overview
General Medicine
Authors
Affiliations
Highly polarized type 2 cytokine responses can be harmful and even lethal to the host if they are too vigorous or persist too long. Therefore, it is important to elucidate the mechanisms that down-regulate these reactions. Interleukin (IL)-13 has emerged as a central mediator of T helper cell (Th)2-dominant immune responses, exhibiting a diverse array of functional activities including regulation of airway hyperreactivity, resistance to nematode parasites, and tissue remodeling and fibrosis. Here, we show that IL-13 receptor (R)alpha2 is a critical down-regulatory factor of IL-13-mediated tissue fibrosis induced by the parasitic helminth Schistosoma mansoni. IL-13Ralpha2 expression was induced after the onset of the fibrotic response, IL-10, IL-13, and Stat6 dependent, and inhibited by the Th1-inducing adjuvant IL-12. Strikingly, schistosome-infected C57BL/6 and BALB/c IL-13Ralpha2-deficient mice showed a marked exacerbation in hepatic fibrosis, despite displaying no change in granuloma size, tissue eosinophilia, or mastocytosis. Fibrosis increased despite the fact that IL-13 levels decreased significantly in the liver and serum. Importantly, pathology was prevented when IL-13Ralpha2-deficient mice were treated with a soluble IL-13Ralpha2-Fc construct, formally demonstrating that their exacerbated fibrotic response was due to heightened IL-13 activity. Together, these studies illustrate the central role played by the IL-13Ralpha2 in the down-regulation of a chronic and pathogenic Th2-mediated immune response.
Intranasal dupilumab improves responsiveness to steroid in an asthma mouse model.
Khalid Salah Al-Sheakly B, Saheb Sharif-Askari F, Sharif-Askari N, Zakri A, Mdkhana B, Wed Abdelaziz Eladham M Inflamm Res. 2025; 74(1):43.
PMID: 39969581 DOI: 10.1007/s00011-024-01991-5.
A Comprehensive Review of Biologics in Phase III and IV Clinical Trials for Atopic Dermatitis.
Waligora-Dziwak K, Danczak-Pazdrowska A, Jenerowicz D J Clin Med. 2024; 13(14).
PMID: 39064040 PMC: 11277805. DOI: 10.3390/jcm13144001.
Leland P, Degheidy H, Lea A, Bauer S, Puri R, Joshi B Clin Transl Med. 2024; 14(5):e1664.
PMID: 38685487 PMC: 11058282. DOI: 10.1002/ctm2.1664.
Potential Indications of Dupilumab in Th-2 Inflammatory Disease.
Ilaria P, Nevena S, Ersilia T, Nicoletta B, Federica T, Di Fraia M Rev Recent Clin Trials. 2023; 19(1):53-61.
PMID: 38141197 DOI: 10.2174/0115748871263396231121060901.
Novel Therapeutic Strategies in the Treatment of Systemic Sclerosis.
Gumkowska-Sroka O, Kotyla K, Mojs E, Palka K, Kotyla P Pharmaceuticals (Basel). 2023; 16(8).
PMID: 37630981 PMC: 10458905. DOI: 10.3390/ph16081066.